Vyome Holdings, Inc
HIND evidence brief
What we can confirm
- BioSniper Score:
- 6.7 / 10
- Market Cap:
- $14.5M
- Lead Asset:
- dbsn device (Preclinical)
What it means
What to watch
Prepared research question
What matters most for HIND—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · HIND
Vyome Holdings, Inc. (HIND) is a clinical-stage specialty pharmaceutical company focused on immune-inflammatory and rare diseases, operating via a US-India innovation corridor and advancing a lead topical gel program for malignant fungating wounds.
Key risk: Cash runway insufficient
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$14.5M
Cash Runway
—
Lead Asset
dbsn device (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates for Vyome Holdings, Inc.
Vyome Holdings, Inc. (HIND) is a clinical-stage specialty pharmaceutical company focused on immune-inflammatory and rare diseases, operating via a US-India innovation corridor and advancing a lead topical gel program for malignant fungating wounds.
- Vyome Holdings was formed on August 15, 2025, via a reverse merger with ReShape Lifesciences, renaming the company and making Vyome Therapeutics a subsidiary [sec_mda · as of 2026-08-12].
- Lead program VT-1953 is a topical gel for malignant fungating wounds, with plans for FDA discussions on a pivotal trial design in Q2 2026 [sec_mda · as of 2026-03-18].
- VB-1953, for moderate to severe acne, has completed Phase II and is Phase 3-ready [sec_mda · as of 2026-08-12].
- Cash and equivalents were $7.9M as of June 30, 2026, with net income of -$0.7M and zero revenue for the quarter [sec].
- The company has incurred significant operating losses since inception and expects to continue doing so for the foreseeable future [sec_mda · as of 2026-08-12].
What works
- Lead program VT-1953 targets an orphan-drug-potential indication (malignant fungating wounds) and is advancing toward a pivotal trial, with FDA discussions planned [sec_mda · as of 2026-03-18].
- VB-1953 for acne is Phase 3-ready after completing a Phase II trial, providing a later-stage pipeline asset [sec_mda · as of 2026-08-12].
- The company leverages a US-India innovation corridor for operational and cost advantages [sec_mda · as of 2026-08-12].
What to weigh
- Cash of $7.9M as of June 30, 2026, is insufficient to complete the pivotal trial of VT-1953 or develop other candidates [sec_mda · as of 2026-05-12].
- The company has zero revenue and has incurred significant operating losses since inception, with no near-term product sales expected [sec_mda · as of 2026-08-12].
- Clinical trials face multiple uncertainties including delays in regulatory approval, enrollment, and safety profile establishment [sec_mda · as of 2026-08-12].
- A civil court notice for ~$95,000 in deferred unpaid salary indicates past financial strain [sec_mda · as of 2026-05-12].
From the filings
Quoted directly from source documents.
Vyome Holdings was formed via a reverse merger on August 15, 2025.
“As a result of the Merger, the Company was renamed "Vyome Holdings, Inc." and Vyome continued under its name as Vyome Therapeutics, Inc., in each case effective before the open of trading on August 15, 2025.”
SEC MD&A · August 12, 2026
Lead program VT-1953 is a topical gel for malignant fungating wounds.
“The lead program, VT-1953, is a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds, potentially an orphan drug designation program.”
SEC MD&A · March 18, 2026
Cash balance as of June 30, 2026, was $7,887,510.
“As of June 30, 2026, we had a cash balance of $7,887,510”
SEC MD&A · August 12, 2026
The company has incurred significant operating losses since inception.
“Since inception, we have incurred significant operating losses.”
SEC MD&A · August 12, 2026
Risks & what to watch (4)›
Key risks
- Cash runway insufficient — Cash of $7.9M as of June 30, 2026, is not enough to complete VT-1953 pivotal trial or develop other candidates [sec_mda · as of 2026-05-12].
- No revenue, ongoing losses — Zero revenue and significant operating losses since inception; material net cash inflows from product sales are uncertain [sec_mda · as of 2026-08-12].
- Clinical trial uncertainties — Delays possible in regulatory approval, enrollment, safety, and efficacy; pivotal trial design not yet finalized [sec_mda · as of 2026-08-12].
- Past salary liability — Civil court notice for ~$95,000 in deferred unpaid salary to a past employee indicates historical financial strain [sec_mda · as of 2026-05-12].
What to watch
- FDA discussions on pivotal trial design for VT-1953, planned for Q2 2026 [sec_mda · as of 2026-03-18].
- Initiation and funding of the VT-1953 pivotal trial, given cash constraints [sec_mda · as of 2026-05-12].
- Progress of VB-1953 toward Phase 3 and any partnership or licensing deals [sec_mda · as of 2026-08-12].
- Ability to raise additional funding through equity, debt, or collaborations to extend runway [sec_mda · as of 2026-03-18].
Sources: News · SEC MD&A · Generated October 7, 2026 · How we verify sources →
Run Vyome Holdings, Inc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Vyome Holdings, Inc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$686K
Lead: Approved
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
9
Total value held
$198K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 25,793 | $55K |
| ubs group ag | 22,675 | $49K |
| focus partners wealth | 14,640 | $31K |
| vanguard fiduciary trust co | 12,195 | $26K |
| vanguard capital management llc | 9,463 | $20K |
| royal bank of canada | 5,856 | $13K |
| tower research capital llc (trc) | 1,391 | $3K |
| citigroup inc | 16 | $34 |
| caitong international asset management co., ltd | 2 | $4 |
Short Interest
as of Apr 22, 2026- % of float
- 3.5%
- Days to cover
- 3.9
- Shares short
- 158,474
- Daily short volume (Jun 5, 2026)
- 39.0%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
HIND short interestGovernance
Frequently asked questions
What is the AI investment thesis for Vyome Holdings, Inc?
Vyome Holdings, Inc. (HIND) is a clinical-stage specialty pharmaceutical company focused on immune-inflammatory and rare diseases, operating via a US-India innovation corridor and advancing a lead topical gel program for malignant fungating wounds.
What is Vyome Holdings, Inc's lead drug candidate?
Vyome Holdings, Inc's most advanced tracked candidate is dbsn device (Preclinical) for type 2 diabetes mellitus.
Who is the CEO of Vyome Holdings, Inc?
Mr. Venkateswarlu Nelabhotla M.B.A. is the chief executive officer of Vyome Holdings, Inc (HIND).
Where is Vyome Holdings, Inc headquartered?
Vyome Holdings, Inc (HIND) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Vyome Holdings, Inc focus on?
Vyome Holdings, Inc develops therapies across Oncology, Ophthalmology, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.